Vivos Therapeutics (VVOS) - רווח נקי למניה (EPS TTM)
Vivos Therapeutics (VVOS) business growth is based on insurance companies' recognition of their apnea treatment methods and physician training. A snapshot of the rolling annual revenue per share helps identify hidden market traps, while -2.06 determines the latest valuation metric. Technological leadership in 3D airway modeling faces a liquidity shortage due to high costs associated with expanding the distribution network.
VVOS (Vivos Therapeutics, Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים
The Vivos Therapeutics business model is attractive due to stable demand for sleep apnea medical technology, which remains independent of macroeconomic fluctuations. This indicator measures net income allocated per common share over a rolling year. By analyzing the 12-month net income per share history, an investor assesses the real return on capital. This price action reflects the company's resilience in a low-cyclicity market. Growth in this metric indicates a fundamental strengthening of the business.
